Vaxcyte (PCVX) Is Up 8.4% After Starting First-in-Human Trial Of Its Strep A Vaccine

Simply Wall St.06-19

Earlier this month, Vaxcyte announced that it has dosed the first participant in its Phase 1, first-in-human trial of VAX-A1, an investigational vaccine targeting Group A Streptococcus, with topline ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644508370?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-19 22:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644508370","market":"nz","top_or_hot":-1,"title":"Vaxcyte (PCVX) Is Up 8.4% After Starting First-in-Human Trial Of Its Strep A Vaccine","media":"Simply Wall St.","content":"<div>\n<p>Earlier this month, Vaxcyte announced that it has dosed the first participant in its Phase 1, first-in-human trial of VAX-A1, an investigational vaccine targeting Group A Streptococcus, with topline ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-is-up-84-after-starting-first-in-human-trial-of\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxcyte (PCVX) Is Up 8.4% After Starting First-in-Human Trial Of Its Strep A Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxcyte (PCVX) Is Up 8.4% After Starting First-in-Human Trial Of Its Strep A Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-19 22:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-is-up-84-after-starting-first-in-human-trial-of><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this month, Vaxcyte announced that it has dosed the first participant in its Phase 1, first-in-human trial of VAX-A1, an investigational vaccine targeting Group A Streptococcus, with topline ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-is-up-84-after-starting-first-in-human-trial-of\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0053671581.USD","symbol_name":"摩根大通美国小盘成长股 A(dist)","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-is-up-84-after-starting-first-in-human-trial-of","article_id":"2644508370","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-is-up-84-after-starting-first-in-human-trial-of","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2644508370","pubTimestamp":1781878947,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier this month, Vaxcyte announced that it has dosed the first participant in its Phase 1, first-in-human trial of VAX-A1, an investigational vaccine targeting Group A Streptococcus, with topline safety and tolerability data expected in the second half of 2027.\nThis milestone advances Vaxcyte’s pipeline into human testing for a pathogen that currently has no approved vaccine, highlighting the company’s effort to address a significant infectious disease burden.\nWe’ll now examine how...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4139":"生物科技","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","PCVX":"Vaxcyte, Inc."},"translate_title":"Vaxcyte(PCVX)在开始其A型链球菌疫苗的首次人体试验后股价上涨8.4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCVX":1.5},"content_text":"Earlier this month, Vaxcyte announced that it has dosed the first participant in its Phase 1, first-in-human trial of VAX-A1, an investigational vaccine targeting Group A Streptococcus, with topline safety and tolerability data expected in the second half of 2027. This milestone advances Vaxcyte’s pipeline into human testing for a pathogen that currently has no approved vaccine, highlighting the company’s effort to address a significant infectious disease burden. We’ll now examine how initiating first-in-human testing for VAX-A1 could reshape Vaxcyte’s investment narrative and pipeline diversification story. Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AdvertisementVaxcyte Investment Narrative RecapTo own Vaxcyte, you need to believe its pneumococcal franchise, led by VAX-31, can eventually transition the company from zero revenue to a sustainable vaccine business. The key near term catalyst remains the OPUS-1 Phase 3 readout for adult VAX-31 in Q4 2026, while the biggest risk is continued high cash burn if late stage data or timelines disappoint. The new VAX-A1 first in human milestone is encouraging for diversification, but does not materially change that near term focus. The VAX-A1 Phase 1 start fits alongside a busy clinical calendar anchored by VAX-31. In February 2026, Vaxcyte reiterated that OPUS-1 adult data are expected in Q4 2026, with OPUS-2 and OPUS-3 following in the first half of 2027, and infant VAX-31 Phase 2 topline mid 2026. Against this backdrop, VAX-A1’s progress adds a second potential franchise, but the timing and importance of those late stage VAX-31 readouts still dominate the upcoming catalyst stack. Yet beneath these pipeline milestones, investors should also be aware of the risk that rising R&D and manufacturing costs could outpace the current cash runway guidance and ... Read the full narrative on Vaxcyte (it's free!)Vaxcyte’s narrative projects $224.6 million revenue and $28.1 million earnings by 2029. This implies an earnings increase of about $794.7 million from -$766.6 million today.Uncover how Vaxcyte's forecasts yield a $109.00 fair value, a 112% upside to its current price.Exploring Other PerspectivesPCVX 1-Year Stock Price Chart By contrast, the most pessimistic analysts saw only about US$15.3 million of revenue and US$1.7 million of earnings by 2029, reminding you that even with VAX A1’s first dosing, opinions on whether early stage uncertainty and extra proof of concept work will pay off can differ widely and may evolve as this new data arrives.Explore 3 other fair value estimates on Vaxcyte - why the stock might be worth over 3x more than the current price!Decide For YourselfDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Vaxcyte research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.Our free Vaxcyte research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vaxcyte's overall financial health at a glance.Seeking Other Investments?Opportunities like this don't last. These are today's most promising picks. Check them out now:Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.Find 45 companies with promising cash flow potential yet trading below their fair value.Explore 31 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644508370","isCrawlerRequest":true}